Bliss GVS Pharma Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling regulatory obligations under SEBI depositories regulations for the quarter ended March 31, 2026.

Regulatory Compliance Filing

The pharmaceutical company filed the mandatory certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, with both the National Stock Exchange of India Limited and BSE Limited on April 02, 2026.

Certificate Confirmation

MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, serving as the company's Registrar and Share Transfer Agent, issued the compliance certificate dated April 01, 2026. The certificate confirms that securities received from depository participants for dematerialisation during Q4FY26 were properly processed and confirmed to the depositories.

Key Compliance Confirmations

The registrar's certificate validates several critical compliance aspects:

• Securities received for dematerialisation were confirmed or rejected to depositories within prescribed timelines
• All securities comprised in certificates have been listed on stock exchanges where earlier issued securities are listed
• Security certificates received for dematerialisation were properly mutilated and cancelled after due verification
• Depository names were substituted in the register of members as registered owners within regulatory timelines

Corporate Communication

Company Secretary Aditi Bhatt signed the filing letter, ensuring proper corporate governance protocols were followed. The submission was also copied to National Securities Depository Limited and Central Depository Services (India) Ltd, maintaining transparency with all relevant depositories.

This quarterly filing demonstrates Bliss GVS Pharma's commitment to maintaining regulatory compliance and ensuring transparent securities management processes for investor protection.

Bliss GVS Pharma Limited has issued an official clarification to stock exchanges regarding speculative media reports about a potential stake acquisition by Anupam Rasayan. The company filed the disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 on February 13, 2026.

Company's Official Response

The pharmaceutical company addressed news reports published in CNBC आवाज़ with the headline "Bliss GVS में हिस्सा ले सकती है अनुपम रसायन" (Anupam Rasayan may take stake in Bliss GVS). The company categorically stated that these reports appear to be speculative in nature and do not originate from any official communication or confirmation by the company.

Current Status of Reported Development

Bliss GVS Pharma clarified that as of the filing date, no decision or arrangement has been crystallized, finalized, or approved by the company's promoters in relation to the news item. The company emphasized that no information or development warrants disclosure under Regulation 30 of the SEBI regulations at this time.

Regulatory Compliance and Investor Advisory

The company reinforced its commitment to regulatory compliance, stating it is a well-governed and law-compliant entity that has consistently ensured timely and appropriate disclosures to stock exchanges. Bliss GVS Pharma specifically advised:

• Investors and the public should rely only on official disclosures made by the company to stock exchanges
• All disclosures are made in accordance with applicable laws and SEBI regulations
• The clarification aims to prevent establishment of false market sentiment based on speculative reports

Company Information

The clarification was signed by Company Secretary Aditi Bhatt and filed with both the National Stock Exchange of India (Symbol: BLISSGVS) and BSE Limited (Scrip Code: 506197). The company maintains its registered office in Mumbai and operates a manufacturing facility in Palghar district.